PFNX stock news

Pfenex (PFNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. Read more
Biotech stocks continued to languish for a third straight week. Negative broader market sentiment and company-specific weakness weighed down on the sector. Pfenex Inc (NYSE: PFNX ) received FDA approval for its biosimilar to Amgen, Inc. (NASDAQ: AMGN )'s Forteo, and Australian biotech Clinuvel Pharmaceuticals Ltd (OTC: CLVLY )'s Scenesse to treat erythropoietic protoporphyria was also given the go-ahead by the regulatory agency. The week also saw the listing of two biotechs following their initial public offerings. The following are some of the key catalysts for biotech stocks in the upcoming week. Conferences American Academy of Ophthalmology (AAO) 2019: Oct. 12-15 in San Francisco, California International Congress And Exhibition on Endocrine And Diabetic Complications: Oct. 14-15 in Sydney, Australia International Conference on Molecular Markers and Cancer Therapeutics: Oct. 14-15 in Abu Dhabi, UAE Annual meeting of Neuro Critical Care Society: Oct. 15-18, in Vancouver 10th Annual Congress on Rare Diseases and Orphan Drugs: Oct. 16-17 in Tokyo, Japan 14th Annual Conference on Nephrology & Renal Care: Oct. 16-17 in Singapore City 2nd International conference on blood disorders: Oct. 17-18 in Osaka, Japan See Also: Attention … Read more
Investors need to pay close attention to Pfenex (PFNX) stock based on the movements in the options market lately. Read more

FDA approves Pfenex's osteoporosis therapy

10:16am, Monday, 07'th Oct 2019
https://www.investing.com/news/general/fda-approves-pfenexs-osteoporosis-therapy-1992692 Read more
Notwithstanding the ESMO conference generating some huge moves in some stocks, last week turned out to be a muted one for biotechs. A few FDA approvals came … Read more
Pfenex Inc (NYSE: PFNX ) has a key binary event coming up: mark your calendar for Oct. 7, when the FDA is scheduled to issue its verdict on the company's lead drug candidate. Through its production platform Pfenex Expression Technology, the biotech Pfenex engages in the development of high-value protein-based therapeutics and vaccines. This thinly traded micro-cap biotech has more than doubled year-to-date. Has the rally run out of steam, or is there further upside ahead? Clinical Pipeline The most advanced product candidate in Pfenex' pipeline, PF708, is inching closer to commercialization. The lead candidate is a therapeutic equivalent of Eli Lilly And Co (NYSE: LLY )'s Forteo, which was approved in 2002 to treat osteoporosis in men and menopausal women who are at high risk of fractures. Forteo's global sales stood at $1.6 billion in 2019. Following the midcycle review of Pfenex's NDA for PF708 in May, the FDA did not identify any issues requiring an Adcom meeting, the company said in its second-quarter earnings release. Read more
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Sept. 9.) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) ( reacted to positive Nuplazid data) Bioanalytical Systems, Inc. (NASDAQ: BASI ) Protagonist Therapeutics Inc (NASDAQ: PTGX ) Scpharmaceuticals Inc (NASDAQ: SCPH ) ZEALAND PHARMA/S ADR (NASDAQ: ZEAL ) Pfenex Inc (NYSE: PFNX ) Down In The Dumps (Biotech stocks that hit 52-week lows on Sept. 9.) Advaxis, Inc. (NASDAQ: ADXS ) (reacted to third-quarter results) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Endologix, Inc. (NASDAQ: ELGX ) Gemphire Therapeutics Inc (NASDAQ: GEMP ) Illumina, Inc. (NASDAQ: ILMN ) Neurotrope Inc (NASDAQ: NTRP ) ( Alzheimer's disease drug did not meet the primary endpoint) Obalon Therapeutics Inc (NASDAQ: OBLN ) Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) Retrophin Inc (NASDAQ: RTRX ) Stealth BioTherapeutics Corp (NASDAQ: MITO ) Surface Oncology Inc (NASDAQ: SURF ) Trinity Biotech plc (NASDAQ: TRIB ) Transenterix Inc (NYSE: TRXC ) See also: Biotech Stock On The Radar: Ardelyx Gears Up For FDA Decision Day Stocks In Focus Translate Bio Discontinues Development Of mRNA Therapy Translate Bio Inc (NASDAQ: TBIO ) said in a clinical pipeline update that it has decided to discontinue the development of MRT5201, a liver-targeted treatment for ornithine transcarbamylase, or OTC, deficiency. Read more
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Sept. 5) Bioanalytical Systems, Inc. (NASDAQ: BASI ) NextCure Inc (NASDAQ: NXTC ) Pfenex Inc (NYSE: PFNX ) Protagonist Therapeutics Inc (NASDAQ: PTGX ) ResMed Inc. (NYSE: RMD ) West Pharmaceutical Services Inc. (NYSE: WST ) Down In The Dumps (Biotech stocks hitting 52-week lows on Sept. 5) Adamis Pharmaceuticals Corp (NASDAQ: ADMP ) BioNano Genomics Inc (NASDAQ: BNGO ) Endologix, Inc. (NASDAQ: ELGX ) Mallinckrodt PLC (NYSE: MNK ) ( retreated amid reports of restructuring ahead of Cleveland opioid litigation) Merit Medical Systems, Inc. (NASDAQ: MMSI ) VBI Vaccines Inc (NASDAQ: VBIV ) Zafgen Inc (NASDAQ: ZFGN ) ( announced decision to explore strategic options) See Also: Biotech Stock On The Radar: Ardelyx Gears Up For FDA Decision Day Stocks In Focus Neon's Process To Predict Neoantigens To Control Tumor Growth Published In Scientific Journal Neon Therapeutics Inc (NASDAQ: NTGN ) announced publication in the scientific journal "Immunity," a breakthrough process for predicting which neoantigens will be presented by MHC Class II molecules in the tumor microenvironment. Read more
Pfenex (PFNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. Read more

EMA accepts Pfenex's MAA for PF708

01:04pm, Thursday, 30'th May 2019
Read more
SAN DIEGO, May 30, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE: PFNX ) and Alvogen today announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) submitted by our partner Alvogen for PF708 (teriparatide). The product is proposed as a therapeutic equivalent in the treatment of osteoporosis to Forteo®. The product is filed with the EMA as a biosimilar in the treatment of osteoporosis to Forsteo®, which achieved $289 million sales in the E.U. and $1.6 billion in global product sales in 2018. This acceptance means the EMA considers the MAA to be complete and initiates the EMA's formal review process. "The acceptance of the PF708 MAA filing is an important milestone for Pfenex and Alvogen and demonstrates that through our collaborative partnership, we continue making progress towards potential approvals beyond the United States," said Eef Schimmelpennink, Chief Executive Officer of Pfenex. "Subject to applicable regulatory approvals, for Europe, PF708 will be commercialized by Theramex, a leading global specialty pharmaceutical company dedicated to Women's Health." "We are very pleased with the EMA's acceptance of the MAA for review. Read more
As of late, it has definitely been a great time to be an investor in Pfenex Inc. (PFNX). Read more
Pfenex (PFNX) delivered earnings and revenue surprises of 52.00% and 84.05%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock? Read more

Pfenex beats by $0.15, beats on revenue

08:33pm, Thursday, 09'th May 2019
Read more

Proudly made at

ROCKIT